Menu
24/05/2006
Herceptin granted UK license
Breast cancer drug Herceptin has been licensed for use in the early stages of the disease in the UK by the European Medicines Agency.
The drug, which is already used in Britain to treat the later stages of breast cancer, will now be appraised by the National Institute of Health and Clinical Excellence to see if it is safe and cost-effective.
NICE is expected to issue guidance on the drug in July.
Herceptin has recently been the subject of several court cases involving women with early stage breast cancer wanting to be treated with the drug on the NHS.
Last year, Barbara Clark, from Somerset, won her case to receive Herceptin on the NHS, followed by Ann Marie Rogers, from Swindon, who won her case in April this year.
Ms Clark welcomed the decision, calling it "great news".
The news was also welcomed by Breast Cancer Campaign CEO Pamela Goldberg, who said: "We congratulate the European Medicines Agency for prioritising the treatment and putting it through the licensing system so quickly.
"Herceptin has previously been available for patients with metastatic breast cancer however recent clinical trials have shown that Herceptin will reduce the recurrence of breast cancer by 46 per cent when used in early stage HER2 positive breast cancer after surgery and chemotherapy.
"This is a significant step for breast cancer research and is a major advance in the treatment of women with early stage breast cancer."
(KMcA)
The drug, which is already used in Britain to treat the later stages of breast cancer, will now be appraised by the National Institute of Health and Clinical Excellence to see if it is safe and cost-effective.
NICE is expected to issue guidance on the drug in July.
Herceptin has recently been the subject of several court cases involving women with early stage breast cancer wanting to be treated with the drug on the NHS.
Last year, Barbara Clark, from Somerset, won her case to receive Herceptin on the NHS, followed by Ann Marie Rogers, from Swindon, who won her case in April this year.
Ms Clark welcomed the decision, calling it "great news".
The news was also welcomed by Breast Cancer Campaign CEO Pamela Goldberg, who said: "We congratulate the European Medicines Agency for prioritising the treatment and putting it through the licensing system so quickly.
"Herceptin has previously been available for patients with metastatic breast cancer however recent clinical trials have shown that Herceptin will reduce the recurrence of breast cancer by 46 per cent when used in early stage HER2 positive breast cancer after surgery and chemotherapy.
"This is a significant step for breast cancer research and is a major advance in the treatment of women with early stage breast cancer."
(KMcA)
Related UK National News Stories
Click here for the latest headlines.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
12 April 2006
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
09 June 2006
Herceptin approved for early breast cancer use on NHS
Breast cancer drug Herceptin has been approved for the treatment of early stage breast cancer on the NHS by the National Institute for Health and Clinical Excellence. Herceptin is effective on the HER2 positive form of breast cancer, which forms around 20% of all breast cancer cases.
Herceptin approved for early breast cancer use on NHS
Breast cancer drug Herceptin has been approved for the treatment of early stage breast cancer on the NHS by the National Institute for Health and Clinical Excellence. Herceptin is effective on the HER2 positive form of breast cancer, which forms around 20% of all breast cancer cases.
17 October 2005
Breast cancer can cost ‘thousands’
Breast cancer can cost sufferers thousands of pounds, a survey by a leading cancer charity has revealed. Macmillan Cancer Relief surveyed 50 cancer patients and found that, on average, they spent almost £2,000 on extra costs during their treatment.
Breast cancer can cost ‘thousands’
Breast cancer can cost sufferers thousands of pounds, a survey by a leading cancer charity has revealed. Macmillan Cancer Relief surveyed 50 cancer patients and found that, on average, they spent almost £2,000 on extra costs during their treatment.
22 October 2010
MRIs May Lead To Unnecessary Breast Surgery
Women could be undergoing unnecessary breast surgery as a result of having magnetic resonance imaging (MRI), says an expert on bmj.com today.
MRIs May Lead To Unnecessary Breast Surgery
Women could be undergoing unnecessary breast surgery as a result of having magnetic resonance imaging (MRI), says an expert on bmj.com today.
-
Northern Ireland WeatherThis Evening and Tonight:Showers, scattered in the evening, will clear by midnight leaving the night dry with clear spells. Perhaps a touch of ground frost. Cloud will spread east towards morning. Minimum temperature 2 °C.
